AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01830556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Group A:Day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes Day 1 Cisplatin 100mg/m2 or Carboplatin AUC 5 day 1-4 5-Fluorouracil 1000 mg/m2 iv 24 h Group B day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes day 1 Paclitaxel 175 mg/m2 day 1 Carboplatin AUC 5 treatment for 6 cycles thereafter day 1 Cetuximab 500 mg/m2 every second week treatment until progress or unacceptable toxicity
Study NCT03720756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nickel-free diet
Description: Subjects follow a nickel-free diet. Lists of acceptable foods will be provided to subjects.
Study NCT03720756 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nickel-free diet
Description: Subjects follow a nickel-free diet. Lists of acceptable foods will be provided to subjects.
Study NCT03101163 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous peripheral blood stem cells and hyaluronic acid
Description: Regimen of intra-articular PBSC and HA injections and postoperative physiotherapy
Study NCT03101163 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid
Description: Regimen of intra-articular HA injections and postoperative physiotherapy
Study NCT02429154 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normocapnia
Description: Normoventilation in order to have an end-tidal carbon dioxide (ETCO2) of 5.5 kiloPascal (kPa)
Study NCT02429154 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mild Hypercapnia
Description: Decrease in minute ventilation in order to increase ETCO2 to 6.5 kPa
Study NCT03061760 — intervention group
Intervention type: PROCEDURE
Intervention: Radical prostatectomy
Description: Radical prostatectomy due to prostate cancer.
Study NCT03061760 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Initial evaluation
Description: Questioners, Ultrasound, Uroflowmetry
Study NCT03061760 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation after 1,3,6,9,12 months
Description: Questioners, Ultrasound, Uroflowmetry
Study NCT01381900 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form=capsule, route=oral administration. One capsule once daily for up to 18 weeks after completing a single-blind placebo run-in period (1 placebo capsule once daily for up to 2 weeks).
Study NCT01381900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100mg
Description: Type=1, unit=mg, number=100, form=capsule, route=oral use. One capsule once daily for up to 18 weeks after completing a single-blind placebo run-in period (1 placebo capsule once daily for up to 2 weeks).
Study NCT01381900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300mg
Description: Type=1, unit=mg, number=300, form=capsule, route=oral use. One capsule once daily for up to 18 weeks after completing a single-blind placebo run-in period (1 placebo capsule once daily for up to 2 weeks).
Study NCT01381900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: The participant's stable dose of background therapy of metformin should be continued throughout the study.
Study NCT01381900 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: The participant's stable dose of background therapy of metformin should be continued throughout the study.
Study NCT01381900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulphonylurea
Description: The participant's stable dose of background therapy of metformin plus sulphonylurea should be continued throughout the study.
Study NCT01381900 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sulphonylurea
Description: The participant's stable dose of background therapy of metformin plus sulphonylurea should be continued throughout the study.
Study NCT01405820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: natalizumab IV
Description: natalizumab for IV Infusion
Study NCT01405820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: natalizumab IV
Description: natalizumab for IV Infusion
Study NCT04486937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S410914 tablet
Description: S410914 tablet
Study NCT03800199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perceptive rehabilitation
Description: The first session will be an education session. Spinous processes will be reference line of the body and patient will lie down on cones. The therapist will ask the patient first to breathe normally and feel the pressure. This will lead the patient to relax and understand cones. Then, the patient will start with the diagrammatic breathing. After breath exercises patient will perform active exercises (include stretching, warming up and cooling down) on supervision. Exercises will include the whole body. Additional to this during the session therapist will ask about the pressure of cones and she will correct the patients' posture. At the end of all the session, the therapist will take a photo of the patients back with the aim of to document the pressure and hyperaemic areas.
Study NCT02596971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezo-G-Benda: Atezolizumab 840 milligrams (mg) intravenously (IV) on Days 1 and 15 of Cycles 2-6, during induction treatment, followed by 840 mg IV on Days 1 and 2 of each month, starting with Month 1, during maintenance treatment. Atezo-G-CHOP: Atezolizumab 1200 mg IV on Day 1 Cycles 2-6, during induction treatment, followed by 840 mg IV on Days 1 and 2 of each month, starting with Month 1. Atezo-R-CHOP: Atezolizumab 1200 mg IV on Day 1 Cycles 2-8, during induction treatment, followed by 1200 mg IV on Day 1 of Cycles 9-25.
Study NCT02596971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine will be administered at a dose of 90 milligrams per square meter (mg/m\^2) IV on Days 1 and 2 of Cycles 1-6, during induction treatment.
Study NCT02596971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered at a dose of 750 mg/m\^2 IV on Day 1 of Cycle 1-6/8, during induction treatment.
Study NCT02596971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin will be administered at a dose of 50 mg/m\^2 IV on Day 1 of Cycle 1-6/8, during induction treatment.
Study NCT02596971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Atezo-G-Benda: Obinutuzumab will be administered at a dose of 1000 mg IV on Days 1, 8, and 15 of Cycle 1 and 1000 mg IV on Day 1 of Cycles 2-6, during induction treatment, followed by 1000 mg IV on Day 1 of every other month, starting with Month 1, during maintenance treatment. Atezo-G-CHOP: Obinutuzumab will be administered at a dose of 1000 mg IV on Days 1, 8, and 15 of Cycle 1 and 1000 mg IV on Day 1 of Cycles 2-6 during induction treatment, followed by 1000 mg IV on Day 1 of every other month, starting with Month 1 during maintenance treatment.
Study NCT02596971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be administered at a dose of 40 mg/m\^2 orally on Days 1-5 of Cycle 1-6/8, during induction treatment. Prednisolone may be given if prednisone is unavailable. The 40 mg/m\^2 dose of prednisone on Day 1 will be replaced by oral corticosteroids given as premedication on Day 1 of Cycle 1 (and subsequent cycles).
Study NCT02596971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine will be administered at a dose of 1.4 mg/m\^2 (maximum 2 mg) IV on Day 1 of Cycle 1-6/8, during induction treatment.
Study NCT02596971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Atezo-R-CHOP: Participants with previously untreated DLBCL will receive rituximab at a dose of 375 mg/m\^2 IV on Day 1 of Cycle 1-8, during induction treatment.
Study NCT03334240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLS003
Description: CLS003
Study NCT03334240 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle
Study NCT04485325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tofacitinib
Description: 5 mg twice daily, p.o.
Study NCT04485325 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: 50 mg once per week, s.c.
Study NCT04636775 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiome
Description: Nasal and buccal swabs, and stool sample, as well as the extracted DNAs
Study NCT00932308 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Western-style diet (WD)
Description: Will comprise of approximately 40% fat, 40% carbohydrates, 20% protein, and 350mg calcium, prepared by the Bionutrition Department using the USDA Nutrient Database.
Study NCT00932308 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prudent Diet (PD)
Description: Will contain approximately 20% fat, 60% carbohydrate, 20% protein, and 1100mg calcium; the diets will consist of a 2-day rotating metabolic menu.
Study NCT01080638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glycoprotein IIb/IIIa inhibitor (abciximab)
Description: patients intracoronary bolus only group and intravenous bolus and 12-hours continuous infusion group bolus:0.25mg/kg body weight,continus 12hrs-0.125ug/kg per minute(maximum: 10ug/min)
Study NCT01816594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab is a humanized monoclonal antibody directed against the extracellular juxtamembrane domain of the HER2 receptor. Administered 4mg/kg i.v. load followed by 2mg/kg i.v. weekly.
Study NCT01816594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is a cytotoxic agent with proven antitumor activity in a variety of solid tumors. The antitumor activity of paclitaxel is based on tubulin-binding and stabilization of non-functional microtubule bundles, thereby blocking normal mitotic spindle development and subsequent cell division. Administered weekly 80mg/m2 i.v.
Study NCT01816594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel is a cytotoxic agent with proven antitumor activity in a variety of solid tumors. The antitumor activity of paclitaxel is based on tubulin-binding and stabilization of non-functional microtubule bundles, thereby blocking normal mitotic spindle development and subsequent cell division. Administered weekly 80mg/m2 i.v.
Study NCT01816594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BKM120 Placebo
Description: Neoadjuvant BKM120 placebo Administered orally 100 mg/day.
Study NCT01643694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic intervention suggesting behavioral activity
Description: 3.6 Those randomized to the intervention will be asked to choose 1 self-directed activity from an electronically provided list sent to them weekly for 10 consecutive weeks. Each activity will take less than 5 minutes to complete. They will also answer 3-5 questions weekly (items taken from the survey items list submitted).
Study NCT01080638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glycoprotein IIb/IIIa inhibitor (abciximab)
Description: patients intracoronary bolus only group and intravenous bolus and 12-hours continuous infusion group bolus:0.25mg/kg body weight,continus 12hrs-0.125ug/kg per minute(maximum: 10ug/min)
Study NCT00114075 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery with gait analysis report
Description: Orthopaedic surgery with access to gait analysis report
Study NCT00114075 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery without gait analysis report
Description: Orthopaedic surgery without access to gait analysis report
Study NCT00460811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linaclotide Acetate
Description: Oral, once daily
Study NCT00460811 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Oral, once daily
Study NCT01100086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reformulated OXY (oxycodone HCl)
Description: Reformulated OXY 10-mg tablet x 1 dose taken without food
Study NCT01100086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Original OxyContin® (OXY) (oxycodone HCl)
Description: Original OxyContin® (OXY) 10-mg tablet x 1 dose taken without food
Study NCT00529503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-40
Description: 2-8 mg/kg IV. Cycle 1: Days -1, 3, 8, 15; Cycles 2, 3: Days 1, 8, 15.
Study NCT00529503 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Volume as equivalent to corresponding SGN 40 dose IV. Cycle 1: Days -1, 3, 8, 15. Cycles 2, 3: Days 1, 8, 15.
Study NCT00529503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m2 IV. Cycle 1: Day -2; Cycles 2, 3: Day 1
Study NCT00529503 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rituximab
Description: 375 mg/m2 IV. Cycle 1: Day -2; Cycles 2, 3: Day 1
Study NCT00529503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 100 mg/m2 IV. Cycles 1-3: Days 1, 2 and 3.
Study NCT00529503 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: etoposide
Description: 100 mg/m2 IV. Cycles 1-3: Days 1, 2 and 3.
Study NCT00529503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC=5 mg/mL min IV. Cycles 1-3: Day 2.
Study NCT00529503 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin
Description: AUC=5 mg/mL min IV. Cycles 1-3: Day 2.
Study NCT00529503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: 5 g/m2 24 hr. IV infusion. Cycles 1-3: Day2.
Study NCT00529503 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ifosfamide
Description: 5 g/m2 24 hr. IV infusion. Cycles 1-3: Day2.
Study NCT00404391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone/Acetaminophen Extended Release
Description: 1 tablet every 12 hours
Study NCT00404391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone/Acetaminophen Extended Release
Description: 2 tablets every 12 hours
Study NCT00404391 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets every 12 hours
Study NCT01051791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus 10mg daily
Description: RAD001 is a pill that will be taken orally (by mouth), at a dose of 10 mg, once a day for 28 days.
Study NCT04295083 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: clay based group study
Description: Clay based group work sessions were applied to the experimental group for 60-90 minutes once a week for 6 weeks. The sessions are composed of structured or semi-structured activities prepared for the purpose of the literature by the researcher for the purposes such as acquiring new solutions and life skills to reduce loneliness and hopelessness of individuals aged 65 and over, and sharing their feelings, thoughts, and memories with other individuals. Clay Study Activity Booklet . Four expert opinions were obtained for the booklet created. Methods such as narration, sharing experiences, group practice, question-answer, learning by doing, imagining were used in the activity program. The physical, psychological, social and mental characteristics of the elderly were taken into consideration in the selection of these methods.
Study NCT02166931 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chicken Essence
Description: BRAND'S® Chicken Essence of 70cc daily for 2 weeks Placebo 70 cc daily for 2 weeks
Study NCT02166931 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Chicken Essence
Description: BRAND'S® Chicken Essence of 70cc daily for 2 weeks Placebo 70 cc daily for 2 weeks
Study NCT03640533 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nanit-Insights
Description: Nanit-Insights is an app-based intervention that provides personalized sleep tips to parents.
Study NCT04747119 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: muscle energy technique
Description: the patient was supine and the therapist fix the lower limb of the affected side then ask the patient to perform isometric contraction for abductors maintained for 3-5 seconds, then the patient was instructed to stop, exhale and relax then the therapist perform further adducted the patient's knee of the affected side as a stretching exercise for Three to five repetitions of these directions were performed.
Study NCT04747119 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional selected physical therapy
Description: 1. life style modification~2. Transcutaneous electrical nerve stimulation (TENS)~3. Flexibility stretching exercises to the hip flexors
Study NCT03391219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: injection bevacizumab
Description: 1.25 mg/0.05 cc bevacizumab
Study NCT03391219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: injection Combined Bevacizumab and Fasudil
Description: 1.25 mg/0.05 cc bevacizumab and 0.15mg/0.05 cc fasudil
Study NCT02000960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triheptanoin
Description: Triheptanoin (C7 oil) is a triglyceride of the anaplerotic odd-chain fatty acid heptonate.
Study NCT02367118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study NCT02367118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01997476 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined EUS, e-PFT and sEUS Testing
Description: advantage of combined EUS, ePFT \& sEUS testing to provide a more definitive diagnostic assessment, rather than each test alone.~Establish the advantage of reduced time and cost of combining EUS and ePFT, rather than when done separately.
Study NCT04287257 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fracture Healing Patch (FHP)
Description: The Fracture Healing Patch (FHP) is an external silicone patch that contains inside micro-electronic modulus, which generates a pulsed electromagnetic field (PEMF) to enhance and improve fracture healing. The FHP is placed under the cast at the fracture site. Throughout the treatment period the FHP produces a pulsed electromagnetic field. The FHP houses a battery, a microelectronic module and a coil that produce the PEMF.
Study NCT04287257 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Fracture Healing Patch (FHP)
Description: The Fracture Healing Patch (FHP) is an external silicone patch that contains inside micro-electronic modulus, which generates a pulsed electromagnetic field (PEMF) to enhance and improve fracture healing. The FHP is placed under the cast at the fracture site. Throughout the treatment period the FHP produces a pulsed electromagnetic field. The FHP houses a battery, a microelectronic module and a coil that produce the PEMF.
Study NCT00840957 — intervention group
Intervention type: BIOLOGICAL
Intervention: infliximab
Description: chimeric monoclonal antibody to Tumor Necrosis Factor-alpha
Study NCT03866512 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Forearm immobilization
Description: Two days of forearm immobilization
Study NCT03866512 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Forearm immobilization
Description: Two days of forearm immobilization
Study NCT04477148 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endotracheal intubation
Description: patients were intubated with 3 different blades
Study NCT01757002 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teens randomized to the experimental arm will receive 4 sessions plus a booster of web-based, tailored asthma management.
Description: Web-based, computer-tailored asthma management intervention delivered in 4 sessions, plus a 6 month booster.
Study NCT01757002 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Teens in the control group will receive generic, web-based asthma education.
Description: Web-based, generic asthma management intervention delivered in 4 sessions.
Study NCT02512302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUN-101 via eFlow nebulizer
Description: 50 mcg glycopyrrolate via Electronic Nebulizer
Study NCT02512302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUN-101 via eFlow nebulizer with activated charcoal
Description: 50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal
Study NCT02512302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seebri® Breezhaler®
Description: 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI
Study NCT02512302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seebri® Breezhaler® with activated charcoal
Description: 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal
Study NCT02512302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate Injection
Description: 50 mcg glycopyrrolate via IV
Study NCT00504712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Sustanon- 200mg- Intramuscular testosterone every 2 weeks
Study NCT00504712 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Saline injection every two weeks